Trial · NCT03123783
Adverse events1,491
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,491
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 2 | 3 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 13 | 53 | 31 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 4 | 38 | 8 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 0 | 14 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 6 | 28 | 10 |
| other | Palpitations | Cardiac disorders | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Palpitations | Cardiac disorders | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Palpitations | Cardiac disorders | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Palpitations | Cardiac disorders | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 1 | 53 | 1 |
| other | Palpitations | Cardiac disorders | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 2 | 38 | 2 |
| other | Palpitations | Cardiac disorders | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 0 | 14 | 0 |
| other | Palpitations | Cardiac disorders | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 0 | 28 | 0 |
| other | Sinus tachycardia | Cardiac disorders | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Sinus tachycardia | Cardiac disorders | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Sinus tachycardia | Cardiac disorders | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 0 | 3 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 3 | 53 | 3 |
| other | Sinus tachycardia | Cardiac disorders | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 1 | 38 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 0 | 14 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03123783/events